Work

Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines

Year: 2025

Type: article

Abstract: OBJECTIVE: A cardiovascular safety issue has been associated with JAK inhibitors (JAKi). This study compares the effects of distinct approved JAKi on endothelial cell (EC) dysfunction and apoptosis during inflammation. METHODS: Massive inflammation was induced in human vascular ECs by tumor necrosis factor (TNF) with interleukin-17A (IL-17A) treated or not treated with tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib at 1 or 10 μM. Levels of IL-6 and IL-8 were measured by enzyme-linked immunosorbent assay. Variations in gene expression of adhesion molecules and factors of blood coagulation and fibrinolysis pathways were quantified by quantitative reverse transcriptase-polymerase chain reaction. Endothelial apoptosis was measured by Annexin V staining. RESULTS: All JAKi decreased IL-6 release of ECs stimulated with TNF+IL-17A. In contrast, only baricitinib and fedratinib decreased IL-8 overproduction, from 1 μM. Fedratinib decreased the up-regulation of vascular adhesion molecule 1 (VCAM-1) and E-selectin expression at 1 and 10 μM. Tofacitinib reduced intercellular adhesion molecule 1 (ICAM-1) and E-selectin induction at 1 μM. However, at 10 μM, tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced induction of VCAM-1 and ICAM-1 triggered by TNF+IL-17A. Peficitinib and fedratinib at 1 and 10 μM decreased tissue factor up-regulation induced by TNF+IL-17A, whereas ruxolitinib was effective only at 1 μM. None of the JAKi could prevent the down-regulation of the anticoagulant molecule thrombomodulin. Fedratinib and peficitinib were both proapoptotic and cytotoxic for ECs. CONCLUSION: All JAKi reduced EC inflammation but most JAKi could not prevent the up-regulation of adhesion molecules or the increase in procoagulant and the decrease in anticoagulant factors triggered by proinflammatory cytokines. Peficitinib and fedratinib exhibited cytotoxic effects causing EC apoptosis.

Source: ACR Open Rheumatology

DOI: 10.1002/acr2.70081

Authors: Aliki Zavoriti, Pierre Miossec

Institutions: Hospices Civils de Lyon, Hôpital Edouard Herriot

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,550